Lab-grown heart muscle heads toward clinical trials through Australian-Danish biotech launch

Heart failure affects more than 60 million people globally, and for those who reach end-stage disease, the only viable treatment is a heart transplant. The problem is simple arithmetic: there are far more failing hearts than donor organs. The waiting list is long, and many patients never reach the top of it.

A new biotech company launched in Denmark aims to offer an alternative. Ibnova Therapeutics will develop stem cell-based treatments that use lab-grown human heart muscle to restore cardiac function after a heart attack, with the goal of reaching first-in-human clinical trials within three to five years.

From Melbourne and Brisbane to Copenhagen

The science behind Ibnova emerged from over a decade of collaborative research between the Murdoch Children's Research Institute (MCRI) in Melbourne and QIMR Berghofer in Brisbane. The research team, led by MCRI Professor Enzo Porrello and QIMR Berghofer Professor James Hudson, along with cardiac surgeons and cardiologists from The Royal Children's Hospital and The Alfred Hospital in Melbourne, developed a method to grow functional human heart muscle from stem cells and demonstrated that transplanting this engineered tissue can restore heart function after a heart attack in animal models.

The company is based in Denmark and backed by two Novo Nordisk Foundation initiatives: the BioInnovation Institute (BII) Venture Lab, which provides early-stage funding and business development support, and the Novo Nordisk Foundation Cellerator, which provides expertise in manufacturing cell therapies to therapeutic-grade standards. The foundational intellectual property was developed with support from the Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), which has research nodes in Copenhagen, Leiden, and Melbourne.

The engineering challenge beyond the biology

Growing heart muscle cells from stem cells is not new. Multiple research groups around the world have demonstrated this capability over the past decade. The harder challenge is engineering those cells into functional tissue that can integrate with a damaged heart, contract in synchrony with existing muscle, and survive long enough to provide lasting benefit.

The MCRI-QIMR Berghofer team's approach involves creating multicellular bioengineered tissues rather than injecting individual cells. This tissue-engineering strategy aims to deliver a structured patch of heart muscle that can be surgically placed onto damaged cardiac tissue, providing both mechanical support and active contractile function.

Animal studies have shown restored heart function and established safety, according to the researchers. But the gap between animal models and human hearts is substantial, involving differences in heart size, immune response, and the chronic nature of heart failure in patients compared to acute injury models in animals.

The manufacturing bottleneck

Even if the biology works in humans, manufacturing poses a distinct set of challenges. Cell therapies require production under stringent Good Manufacturing Practice (GMP) conditions, with quality controls at every step to ensure consistency, sterility, and potency. Scaling from laboratory-sized tissue patches to production volumes sufficient for clinical trials, and eventually commercial supply, is one of the most significant hurdles in the cell therapy field.

The Cellerator partnership is specifically designed to address this bottleneck, providing the manufacturing expertise and infrastructure needed to produce engineered heart tissue at therapeutic grade. Executive Director Andrew Laskary described the company's strategy as aligning manufacturing readiness, regulatory strategy, and clinical partnerships in parallel rather than sequentially.

What we do not know yet

The animal data demonstrating efficacy and safety have not been published in the press materials in sufficient detail to evaluate independently. The specific cell types used, the size and composition of the engineered tissue, the animal models tested, and the duration of follow-up are all important variables that will need scrutiny as the company moves toward regulatory submissions.

Immune rejection remains a central concern for any allogeneic cell therapy, where the transplanted cells come from a donor rather than the patient. Whether the engineered heart tissue will require lifelong immunosuppression, and whether the risks of immunosuppression are acceptable in heart failure patients who are already medically fragile, are questions that clinical trials will need to address.

The three-to-five-year timeline for first-in-human trials is ambitious. Cell therapy development timelines have historically been optimistic, with manufacturing challenges, regulatory requirements, and clinical protocol design frequently introducing delays. The company's access to established infrastructure through BII and the Cellerator may mitigate some of these risks, but the timeline should be understood as a target rather than a commitment.

For the millions of heart failure patients worldwide who have no access to transplantation, the prospect of a lab-grown alternative is compelling. Whether Ibnova can convert a decade of academic research into a clinical reality will depend on the unglamorous work of manufacturing, regulation, and trial design that lies between a laboratory proof of concept and a treatment that reaches patients.